|Assessment Status||Rapid Review Complete|
|Drug||Aclidinium bromide/formoterol fumarate dihydrate|
|Indication||For treatment to relieve symptoms in adult patients with COPD. (Maintenance bronchodilator)|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended at submitted price.|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.